1. Home
  2. DYAI vs KSCP Comparison

DYAI vs KSCP Comparison

Compare DYAI & KSCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYAI
  • KSCP
  • Stock Information
  • Founded
  • DYAI 1979
  • KSCP 2013
  • Country
  • DYAI United States
  • KSCP United States
  • Employees
  • DYAI N/A
  • KSCP N/A
  • Industry
  • DYAI Biotechnology: Biological Products (No Diagnostic Substances)
  • KSCP Telecommunications Equipment
  • Sector
  • DYAI Health Care
  • KSCP Telecommunications
  • Exchange
  • DYAI Nasdaq
  • KSCP Nasdaq
  • Market Cap
  • DYAI 54.4M
  • KSCP N/A
  • IPO Year
  • DYAI 2004
  • KSCP 2022
  • Fundamental
  • Price
  • DYAI $1.40
  • KSCP $2.87
  • Analyst Decision
  • DYAI Strong Buy
  • KSCP Strong Buy
  • Analyst Count
  • DYAI 1
  • KSCP 2
  • Target Price
  • DYAI $6.00
  • KSCP $12.50
  • AVG Volume (30 Days)
  • DYAI 59.0K
  • KSCP 271.4K
  • Earning Date
  • DYAI 03-26-2025
  • KSCP 05-15-2025
  • Dividend Yield
  • DYAI N/A
  • KSCP N/A
  • EPS Growth
  • DYAI N/A
  • KSCP N/A
  • EPS
  • DYAI N/A
  • KSCP N/A
  • Revenue
  • DYAI $3,495,389.00
  • KSCP $10,805,000.00
  • Revenue This Year
  • DYAI $51.30
  • KSCP $18.72
  • Revenue Next Year
  • DYAI $73.26
  • KSCP $45.28
  • P/E Ratio
  • DYAI N/A
  • KSCP N/A
  • Revenue Growth
  • DYAI 20.58
  • KSCP N/A
  • 52 Week Low
  • DYAI $0.93
  • KSCP $2.52
  • 52 Week High
  • DYAI $2.67
  • KSCP $31.50
  • Technical
  • Relative Strength Index (RSI)
  • DYAI 48.73
  • KSCP 21.33
  • Support Level
  • DYAI $1.33
  • KSCP $2.52
  • Resistance Level
  • DYAI $1.45
  • KSCP $4.25
  • Average True Range (ATR)
  • DYAI 0.10
  • KSCP 0.36
  • MACD
  • DYAI 0.00
  • KSCP 0.03
  • Stochastic Oscillator
  • DYAI 48.28
  • KSCP 13.06

About DYAI Dyadic International Inc.

Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Share on Social Networks: